Analysts have been waiting--and waiting--for drugmakers to realize the growth they've predicted for the obesity market. And with a couple of pharma companies preparing to pony up R&D and marketing resources for their obesity products, it could finally be on the way.
With Contrave, Takeda is trying to go where no new-age weight-loss drugmakers have gone before. That means achieving the ultimate marketing goal of getting physicians to back its therapy, patients to stick with it and payers to cover it. And to help it take a shot at that trifecta, it's putting a force of 900 reps behind the drug.
Takeda didn't bring on non-Japanese COO Christophe Weber for nothing. The Osaka-based drugmaker, still faltering in the wake of its patent loss on diabetes champ Actos, was looking for a shake-up. And now, as promised, the blueprints for a new, reorganized company structure are here.
Sanofi's dengue vaccine isn't slated to hit the market until late next year, pending approval, but it already has some competition on the horizon. Takeda has its eye on nods in the U.S. and Europe for its own candidate by the 2017-18 fiscal year, it says.
Legal experts have insisted there is no way that a $9 billion punitive damage award against Takeda Pharmaceutical and Eli Lilly for hiding Actos risks can stand. But the two companies are still sweating that one out after a federal judge refused to throw out the verdict and its mammoth award on Thursday.
The dengue vaccine market may not exist yet, but once it does, it's in for a big growth spurt within the next 6 years, a recent report says. And while market watchers expect Sanofi's candidate to lead the pack, by the time 2020 rolls around, Takeda could be right behind it in the battle for market share.
Christophe Weber, Takeda's anointed next CEO, sees a brighter future through specialization for the Japanese drugmaker, promising to focus only on therapeutic areas where it can lead, leaving behind losing programs.
Takeda's board swept aside concerns over having the company run by a non-Japanese executive, setting up Frenchman Christophe Weber to carry out the plans he believes are needed to turn around the faltering drugmaker.
Christophe Weber is next in line for the throne at Takeda, and the former GlaxoSmithKline exec has a mind to grow the Japanese pharma through dealmaking, hoping to refill the in-transition company's pipeline and expand in emerging markets.
Takeda, Japan's largest drugmaker, has gone through a series of reorganizations in its efforts to take a bigger share of the global market, a process that has included recruiting leadership outside of its native country. That's not sitting very well with some former executives.